Products for Research Use Only

Gefurulimab

CAT: 0804-HY-P99638-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99638-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Gefurulimab (ALXN-1720) is a high-affinity antibody inhibitor targeting complement protein C5, which can specifically bind to C5 and inhibit its cleavage into C5a and C5b. Gefurulimab can block the activation of the terminal complement pathway and reduce inflammatory damage. Gefurulimab can effectively reduce the formation of membrane attack complex (MAC) and has good pharmacokinetic properties. Gefurulimab can be used to study kidney and autoimmune diseases related to abnormal activation of the complement system, such as IgA nephropathy, lupus nephritis, and myasthenia gravis[1][2][3].
CAS Number
2456407-94-4
Product Name Alternative
ALXN-1720
UNSPSC
12352203
Target
Complement System
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/gefurulimab.html
Purity
97.88
Solubility
10 mM in DMSO
Smiles
[Gefurulimab]
Molecular Weight
(28.17 kDa)
References & Citations
[1]Sandra Rayego-Mateos, et al. Targeting inflammation to treat diabetic kidney disease: the road to 2030. Kidney Int. 2022 Dec 5:S0085-2538 (22) 01017-1.|[2]Mullin M, et al. Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions. MAbs. 2024 Jan-Dec;16 (1) :2341443.|[3]Miwa T, et al. Expansion of Anticomplement Therapy Indications from Rare Genetic Disorders to Common Kidney Diseases. Annu Rev Med. 2024 Jan 29;75:189-204.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3